Blueprint Medicines (NASDAQ:BPMC) Upgraded to “Outperform” at Oppenheimer

Oppenheimer upgraded shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) from a market perform rating to an outperform rating in a report issued on Friday, reports. The brokerage currently has $85.00 price objective on the biotechnology company’s stock. Several other research firms have also recently commented on BPMC. initiated coverage on shares of […]

Leave a Reply

Your email address will not be published.

Previous post Piper Sandler Lowers ChampionX (NASDAQ:CHX) Price Target to $38.00
Next post Initiates Coverage on OncoCyte (NASDAQ:OCX)